Deep Dive: Independent Evidence Review on Flu, RSV, and COVID Protection for Infants — Background, What Changed, Viewpoints, and What to Watch (October 2026)

# Deep Dive: Independent Evidence Review on Flu, RSV, and COVID Protection for Infants

## Background

Respiratory virus season brings overlapping risks from influenza, RSV, and COVID-19 for infants and young children. Infants under 6 months are especially vulnerable to RSV hospitalization; flu remains a leading cause of vaccine-preventable pediatric death; and COVID continues to circulate. Maternal vaccination and infant monoclonal antibodies have become central tools.

The Vaccine Integrity Project, in collaboration with the American Medical Association, completed an independent evidence review of studies published primarily from August 2025 through June 2026. The review screened nearly 19,000 studies across the three viruses and identified 299 eligible studies. Results informed joint 2026–27 recommendations from the AAP, AAFP, ACOG, and IDSA.

## What changed

- **Influenza:** Across eight surveillance seasons, vaccination was 80% effective against laboratory-confirmed influenza-associated death in children 6 months to 17 years. Among children with underlying conditions, effectiveness against hospitalization or ED visits was 48%.
- **RSV:** Maternal Abrysvo vaccination reduced infant hospitalization risk 51–70%. Nirsevimab reduced RSV hospitalization 63.6–93% in the first season, regardless of timing. No association with preterm birth was found in comparative studies of maternal RSV vaccination.
- **COVID-19:** Maternal vaccination reduced COVID-related hospital contacts in infants during the first two months of life by 50–54%. In children 9 months to 4 years, vaccination was associated with a 76% reduction in COVID-related pediatric ED visits.

The review found no new pediatric safety signals in comparative studies of currently recommended immunizations.

## Competing viewpoints

Supporters of the independent review emphasize that it fills a need for transparent, peer-reviewed synthesis when advisory processes face disruption or scrutiny. They point to the large effect sizes against severe outcomes as actionable for clinic conversations.

Critics or cautious voices note remaining gaps (duration of protection for adult RSV vaccines, real-world uptake of maternal vaccines) and stress that individual risk-benefit discussions remain essential. Some families prefer delayed or selective immunization based on personal risk assessment. The review itself does not resolve every policy debate; it documents the evidence base for currently recommended products.

## What to watch next

- Uptake of maternal RSV vaccination in the September–March window and nirsevimab administration before discharge or at the first well-child visit.
- Expanded second-season eligibility for certain high-risk infants 8–19 months.
- Local surveillance for early RSV or flu activity.
- Any further independent or society updates as the 2026–27 season progresses.
- Outcomes from ongoing trials of additional monoclonal antibodies (e.g., clesrovimab).

Parents can use the numbers above when preparing for clinic visits. Ask specifically about first-season protection if your infant was not covered by maternal Abrysvo given ≥14 days before birth.

*This summary is for information only and is not medical advice. Decisions about immunization belong with you and your clinician.*

Sources: Vaccine Integrity Project / AMA 2026–27 respiratory season evidence review; Contemporary Pediatrics; CIDRAP coverage.